Udo-Michael Goehring

1.5k total citations · 1 hit paper
23 papers, 1.1k citations indexed

About

Udo-Michael Goehring is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Udo-Michael Goehring has authored 23 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 9 papers in Cardiology and Cardiovascular Medicine and 7 papers in Physiology. Recurrent topics in Udo-Michael Goehring's work include Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers), Heart Failure Treatment and Management (9 papers) and Asthma and respiratory diseases (7 papers). Udo-Michael Goehring is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (19 papers), Heart Failure Treatment and Management (9 papers) and Asthma and respiratory diseases (7 papers). Udo-Michael Goehring collaborates with scholars based in United States, United Kingdom and Switzerland. Udo-Michael Goehring's co-authors include Peter M.A. Calverley, Klaus F. Rabe, Fernando J. Martínez, Leonardo M. Fabbri, Søren Kristiansen, Manja Brose, Dirk Bredenbröker, Frank Richard, Jadwiga A. Wedzicha and Paul Rowe and has published in prestigious journals such as The Lancet, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Udo-Michael Goehring

20 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

2009 575 citations Peter M.A. Calverley, Klaus F. Rabe et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Udo-Michael Goehring United States	8	860	651	248	138	66	23	1.1k
Stephanie Harris United States	7	625 0.7×	573 0.9×	36 0.1×	15 0.1×	41 0.6×	17	781
David Bellamy United Kingdom	11	193 0.2×	223 0.3×	149 0.6×	35 0.3×	13 0.2×	28	531
S. Edwards United Kingdom	5	203 0.2×	127 0.2×	113 0.5×	39 0.3×	10 0.2×	8	387
Likurgos Kolilekas Greece	13	531 0.6×	185 0.3×	66 0.3×	87 0.6×	21 0.3×	22	701
Aditi Shahane United States	6	159 0.2×	252 0.4×	22 0.1×	63 0.5×	30 0.5×	11	597
Hisham Nassar Israel	14	223 0.3×	53 0.1×	76 0.3×	235 1.7×	31 0.5×	33	658
Kari Hortos United States	8	209 0.2×	267 0.4×	61 0.2×	11 0.1×	30 0.5×	11	800
Nihad Tamimi United Kingdom	10	152 0.2×	50 0.1×	83 0.3×	33 0.2×	40 0.6×	17	596
Albert‐Jan L.H.J. Aarnoudse Netherlands	11	90 0.1×	52 0.1×	188 0.8×	251 1.8×	7 0.1×	20	771

Countries citing papers authored by Udo-Michael Goehring

Since Specialization

Citations

This map shows the geographic impact of Udo-Michael Goehring's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Udo-Michael Goehring with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Udo-Michael Goehring more than expected).

Fields of papers citing papers by Udo-Michael Goehring

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Udo-Michael Goehring. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Udo-Michael Goehring. The network helps show where Udo-Michael Goehring may publish in the future.

Co-authorship network of co-authors of Udo-Michael Goehring

This figure shows the co-authorship network connecting the top 25 collaborators of Udo-Michael Goehring. A scholar is included among the top collaborators of Udo-Michael Goehring based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Udo-Michael Goehring. Udo-Michael Goehring is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosano, Giuseppe, Piotr Ponikowski, Cristiana Vitale, et al.. (2023). Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial. Cardiovascular Diabetology. 22(1). 215–215.

Bateman, Eric D., Udo-Michael Goehring, Frank Richard, & Henrik Watz. (2016). Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. Journal of Allergy and Clinical Immunology. 138(1). 142–149.e8. 44 indexed citations

Watz, Henrik, et al.. (2016). Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE). PA308–PA308. 1 indexed citations

Martínez, Fernando J., Peter M.A. Calverley, Udo-Michael Goehring, et al.. (2015). Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. The Lancet. 385(9971). 857–866. 242 indexed citations

Martínez, Fernando J., Peter M.A. Calverley, Udo-Michael Goehring, et al.. (2015). Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy. OA482–OA482. 3 indexed citations

Rennard, Stephen I., Shawn X. Sun, Stavros Tourkodimitris, et al.. (2014). Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. International Journal of COPD. 9. 657–657. 10 indexed citations

Calverley, Peter, Leonardo M. Fabbri, Fernando J. Martínez, et al.. (2013). Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD. European Respiratory Journal. 42(Suppl 57). 3034–3034. 1 indexed citations

Hanania, Nicola A., Peter M.A. Calverley, Mark T. Dransfield, et al.. (2013). Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respiratory Medicine. 108(2). 366–375. 22 indexed citations

Zheng, Jinping, Jinghua Yang, Xiangdong Zhou, et al.. (2013). Roflumilast for the Treatment of COPD in an Asian Population. CHEST Journal. 145(1). 44–52. 30 indexed citations

10.

White, William B., Glen E. Cooke, Peter R. Kowey, et al.. (2013). Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD. CHEST Journal. 144(3). 758–765. 67 indexed citations

11.

Wedzicha, Jadwiga A., Klaus F. Rabe, Fernando J. Martínez, et al.. (2013). Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype. CHEST Journal. 143(5). 1302–1311. 81 indexed citations

12.

Rennard, Stephen I., Shawn X. Sun, Stavros Tourkodimitris, et al.. (2012). Effect Of Roflumilast Treatment Added To Tiotropium On Dyspnea In Patients With Chronic Obstructive Pulmonary Disease. A2261–A2261. 2 indexed citations

13.

Bateman, Eric D., José Roberto Jardim, Udo-Michael Goehring, Manja Brose, & Peter Calverley. (2012). Effect of roflumilast on hospitalizations in COPD patients. 40. 2109. 2 indexed citations

14.

Hui, David, Aziah Ahmad Mahayiddin, Camilo C. Roa, et al.. (2011). Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial. European Respiratory Journal. 38(Suppl 55). p3364–p3364. 1 indexed citations

15.

Hanania, Nicola A., Mark T. Dransfield, Udo-Michael Goehring, Hassan Lakkis, & Paul Rowe. (2011). Efficacy Of Roflumilast In Current And Former Smokers With Chronic Obstructive Pulmonary Disease. A3090–A3090. 1 indexed citations

16.

McIvor, Andrew, Fernando J. Martínez, Manja Brose, & Udo-Michael Goehring. (2010). Efficacy of Roflumilast in Chronic Obstructive Pulmonary Disease Patients With or Without Inhaled Corticosteroid Pretreatment. CHEST Journal. 138(4). 464A–464A. 1 indexed citations

17.

Hanania, Nicola A., Eric Bateman, Peter M.A. Calverley, et al.. (2010). Benefits of Roflumilast Treatment on Exacerbation Outcomes in Patients With COPD: Pooled Results From Two Pivotal 12-Month Studies. CHEST Journal. 138(4). 801A–801A. 1 indexed citations

18.

Martínez, Fernando J., Andrew McIvor, Manja Brose, Thomas Larsson, & Udo-Michael Goehring. (2010). Benefit of Roflumilast Therapy Added to Salmeterol in Patients With Varying Chronic Obstructive Pulmonary Disease Severity. CHEST Journal. 138(4). 467A–467A. 4 indexed citations

19.

Martínez, Fernando J., Klaus F. Rabe, Emiel F.�M. Wouters, et al.. (2010). Time Course And Reversibility Of Weight Decrease With Roflumilast, A Phosphodiesterase 4 Inhibitor. A4441–A4441. 7 indexed citations

20.

Calverley, Peter M.A., Klaus F. Rabe, Udo-Michael Goehring, et al.. (2009). Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. The Lancet. 374(9691). 685–694. 575 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact